Added to YB: 2026-09-11
Pitch date: 2026-09-09
SANA [neutral]
Sana Biotechnology, Inc.
Author Info
No bio for this author
Company Info
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
Market Cap
$949.0M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.01
P/E
-4.15
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Presentations, Wells Fargo Day 1 section 1 - Sana Biotechnology, Inc.
SANA (quick overview): Sana Biotechnology is nearing human validation for two differentiated platforms with transformative potential but very high risk. The first major opportunity, SC451, aims to restore insulin production in type 1 diabetes without immunosuppression; the second is an in vivo CD19 CAR-T program emphasizing cell-specific delivery and separation of T-cell entry from activation. Both remain clinically unvalidated, making first human data — not platform sophistication — the key determinant of valuation.
Read full article (1 min)